To Compare Relaxed Rotational Thromboelastometry Cut-offs With Standard Cut-offs for Guiding Blood Product Use Before Invasive Procedures in Cirrhosis and Acute on Chronic Liver Failure Patients
NCT05672589 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1050
Last updated 2023-06-18
Summary
Hypothesis
Relaxed ROTEM cutoff guided blood product transfusion will result in less blood products use without increasing bleeding complications for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients
AIM:- To evaluate the efficacy and safety of Relaxed threshold (as compared to conventional thresholds) for blood product transfusion for invasive procedures in cirrhosis or acute on chronic liver failure (ACLF) patients
Objective -
Primary objective:
To compare the reduction in amount of total component transfused (ml/kg) in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
Secondary objectives:
To compare the amount of FFP (ml/kg) transfused in Relaxed Rotational Thromboelastometry cut off based versus Standard Rotational Thromboelastometry cut off based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the amount of Platelet (ml/kg) transfused in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the amount of cryoprecipitate (ml/kg) transfused in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the bleeding rate in Relaxed Rotational Thromboelastometry cut off based versus Conventional Rotational Thromboelastometry cut off based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the rate of transfusion reactions in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
To compare the cost incurred in Relaxed Rotational Thromboelastometry based versus Conventional Rotational Thromboelastometry based transfusion strategy in cirrhosis or acute on chronic liver failure (ACLF) patients.
Conditions
- Liver Cirrhosis
- Acute on Chronic Liver Failure
Interventions
- DIAGNOSTIC_TEST
-
Relaxed Rotational Thromboelastometry
Relaxed rotational thromboelastometry will be done 12 hr,24 hr,48 hr, 72 hr and if patients. bleed.
- DIAGNOSTIC_TEST
-
Standard Coagulation Tests
Standard coagulation tests will be done baseline,12 hr,24 hr,48 hr, 72 hr and if patients bleed.
Sponsors & Collaborators
-
Institute of Liver and Biliary Sciences, India
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-02
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- India
Study Locations
More Related Trials
-
Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis
NCT02307409 ·Status: COMPLETED
-
Global Coagulation Assessment in Cirrhosis and ACLF
NCT04332484 ·Status: COMPLETED
-
Impact of Continuous Renal Replacement Therapy on Systemic Hemodynamics and Lactate Clearance in Critically Ill Cirrhotics With Septic Shock.
NCT04949178 ·Status: UNKNOWN
-
The Utility of Thromboelastography in Cirrhotic Patients Undergoing Endoscopic Procedures
NCT02990273 ·Status: TERMINATED ·Phase: NA
-
Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease
NCT02366845 ·Status: COMPLETED ·Phase: PHASE4
-
Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis
NCT02526303 ·Status: WITHDRAWN ·Phase: NA
-
Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock
NCT06556472 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure
NCT02718079 ·Status: COMPLETED ·Phase: NA
-
Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic
NCT03580577 ·Status: UNKNOWN
-
The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis:A Multicenter RCT
NCT02630095 ·Status: UNKNOWN ·Phase: PHASE4
-
Portal Blood Flushes in the Peri-Reperfusion Stage of Liver Transplantation
NCT03563404 ·Status: COMPLETED
-
To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase
NCT02788240 ·Status: TERMINATED ·Phase: NA
-
Portal Pressure Effects of Phlebotomy Combined to Vasopressin Use in Cirrhotic Patients Undergoing Liver Transplantation
NCT04472312 ·Status: COMPLETED
-
To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure
NCT02573727 ·Status: COMPLETED ·Phase: NA
-
RCA for CRRT in Liver Failure and High Risk Bleeding Patients
NCT03791190 ·Status: UNKNOWN ·Phase: NA
-
Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).
NCT01946360 ·Status: COMPLETED ·Phase: NA
-
Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure
NCT02737345 ·Status: COMPLETED
-
Graft Inflow Modulation for Portal Hyper-perfusion in Live Donor Liver Transplantation
NCT04252794 ·Status: COMPLETED ·Phase: NA
-
Haemostatic Imbalance in Patients With Chronic Liver Disease
NCT03589430 ·Status: UNKNOWN
-
To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.
NCT06066814 ·Status: UNKNOWN
-
Anticoagulation for Advanced Cirrhotic Patients After TIPS
NCT03005444 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure
NCT01582087 ·Status: TERMINATED
-
The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis
NCT02398357 ·Status: UNKNOWN ·Phase: PHASE4
-
Incidence and Predictors of Bleeding Diathesis Development Due to DIC in Cirrhosis and ACLF Patients Undergoing CRRT
NCT04960163 ·Status: UNKNOWN
-
Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)
NCT04050683 ·Status: COMPLETED ·Phase: NA